Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears ... and R&D facility is in Cardiff, UK. For more information visit ...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous ... Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit ...
Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled “Oral Rapamycin Nanoparticle Preparations and Use ...
The company recently received Fast Track designation from the FDA for eRapa, held a productive Type C meeting to finalize the Phase 3 protocol, and appointed clinical research organizations (CROs ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears ... and R&D facility is in Cardiff, UK. For more information visit ...
The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six ... R&D facility is in Cardiff, UK. For more information visit ...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback